18 completed, 1 terminated. 19 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 19 | Completed 18, Terminated 1 |
| Phase 2 | 3 | Completed 3 |
Follow NASH - Nonalcoholic Steatohepatitis: new trials by email Literature Review of NASH - Nonalcoholic Steatohepatitis trials Research Report on NASH - Nonalcoholic Steatohepatitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of ALG-055009 in Healthy Volunteers and Subjects With Hyperlipidemia ALG-055009, Placebo - NASH - Nonalcoholic Steatohepatitis | Phase 1 | Completed | Aligos Therapeutics | 98 | 2021-12-01 | 2023-09-25 |
| Pemvidutide (ALT-801) DDI Study in Healthy Volunteers Pemvidutide, Metformin, Atorvastatin - NASH - Nonalcoholic Steatohepatitis | Phase 1 | Completed | Altimmune, Inc. | 40 | 2021-09-15 | 2025-06-24 |
| PK Study of Liquid Formulation of BIO89-100 in Subjects With NASH With Compensation Cirrhosis BIO89-100 - NASH - Nonalcoholic Steatohepatitis | Phase 1 | Completed | 89bio, Inc. | 8 | 2021-08-16 | 2022-03-02 |
| A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of SNP-630 in Health Subjects. SNP-630 - NASH - Nonalcoholic Steatohepatitis | Phase 1 | Completed | Sinew Pharma Inc. | 28 | 2021-07-22 | 2021-10-11 |
| AVIATION Study: A Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TERN-201 in Patients With Non-Cirrhotic Non-Alcoholic Steatohepatitis TERN-201, Placebo - NASH - Nonalcoholic Steatohepatitis | Phase 1 | Completed | Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 52 | 2021-05-20 | 2024-06-07 |
| Study to Assess the Safety, Tolerability, and Pharmacokinetics of PXL770 in Healthy Subjects. PXL770 - NASH - Nonalcoholic Steatohepatitis | Phase 1 | Completed | Poxel SA | 16 | 2021-03-08 | 2022-07-01 |
| Multiple Ascending Dose Study of HU6 in High BMI Volunteers HU6 - NASH - Nonalcoholic Steatohepatitis | Phase 1 | Completed | Rivus Pharmaceuticals, Inc. | 30 | 2021-01-04 | 2021-08-16 |
| Ascending Dose Study of HU6 in Healthy Volunteers HU6 - NASH - Nonalcoholic Steatohepatitis | Phase 1 | Completed | Rivus Pharmaceuticals, Inc. | 64 | 2020-08-12 | 2021-05-04 |
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BLD-0409 in Healthy Subjects BLD-0409, Control: Placebo - Chronic Liver Disease, NASH - Nonalcoholic Steatohepatitis | Phase 1 | Completed | Blade Therapeutics | 80 | 2020-01-10 | 2021-06-04 |
| Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EYP001a in Healthy Volunteers and Nonalcoholic Steatohepatitis Patients EYP001a - NASH - Nonalcoholic Steatohepatitis, Healthy | Phase 1 | Completed | Enyo Pharma | 16 | 2019-06-11 | 2020-09-25 |
| Safety and Tolerability of HepaStem in Patients With Cirrhotic and Pre-cirrhotic NASH Patients HepaStem - NASH - Nonalcoholic Steatohepatitis | Phase 1 / Phase 2 | Completed | Cellaion SA | 23 | 2019-04-09 | 2020-10-14 |
| Spironolactone Therapy In Young Women With NASH Spironolactone 100mg, Placebo oral capsule - NASH - Nonalcoholic Steatohepatitis | Phase 1 / Phase 2 | Completed | University of California, San Francisco | 20 | 2019-01-09 | 2025-03-26 |
| A Drug-drug Interaction Study to Investigate the Effect of Coadministration of EDP-305 on the PK of a Combined Oral Contraceptive in Healthy Female Subjects EDP-305, Oral Contraceptive - NASH - Nonalcoholic Steatohepatitis | Phase 1 | Completed | Enanta Pharmaceuticals, Inc | 43 | 2018-11-27 | 2019-07-24 |
| Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects MGL-3196 - Hepatic Impairment, NASH - Nonalcoholic Steatohepatitis | Phase 1 | Completed | Madrigal Pharmaceuticals, Inc. | 87 | 2018-10-25 | 2023-10-05 |
| Absorption, Metabolism and Excretion (AME) Study of [14C]EDP-305 in Healthy Male Subjects EDP-305 - NASH - Nonalcoholic Steatohepatitis | Phase 1 | Completed | Enanta Pharmaceuticals, Inc | 8 | 2018-10-05 | 2018-11-21 |
| Drug-drug Interaction Study Between EDP-305, Fluconazole and Quinidine in Healthy Volunteers Fluconazole, Quinidine, EDP-305 - NASH - Nonalcoholic Steatohepatitis | Phase 1 | Completed | Enanta Pharmaceuticals, Inc | 48 | 2018-07-19 | 2018-12-05 |
| Study of Gemcabene in Adults With FPLD 300mg Gemcabene, 600mg Gemcabene - Familial Partial Lipodystrophy, Hypertriglyceridemia | Phase 1 / Phase 2 | Completed | Elif Oral | 5 | 2018-03-13 | 2020-08-17 |
| Safety Evaluation of IV Tc 99m Tilmanocept and Comparison of Imaging With Sulfur Colloid in Subjects With and Without NASH Tc 99M Sulfur Colloid, Tc99m-tilmanocept - Nonalcoholic Steatohepatitis, NASH - Nonalcoholic Steatohepatitis | Phase 1 | Terminated | Navidea Biopharmaceuticals | 6 | 2017-12-06 | 2024-12-24 |
| Drug-drug Interaction Study Between EDP-305, Intraconazole and Rifampin in Healthy Volunteers intraconazole, Rifampin, EDP 305 - NASH - Nonalcoholic Steatohepatitis | Phase 1 | Completed | Enanta Pharmaceuticals, Inc | 48 | 2017-07-11 | 2017-11-06 |
Non-alcoholic Fatty Liver Disease (19) · Fatty Liver (1) · Hypertriglyceridemia (1) · Lipodystrophy, Familial Partial (1) · Liver Cirrhosis (1)
Digestive System Diseases (19) · Liver Diseases (19) · Fatty Liver (18) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Dyslipidemias (1) · Fibrosis (1) · Genetic Diseases, Inborn (1) · Hyperlipidemias (1) · Laminopathies (1) · Lipid Metabolism Disorders (1) · Lipid Metabolism, Inborn Errors (1) · Lipodystrophy (1) · Metabolic Diseases (1) · Nutritional and Metabolic Diseases (1) · Pathologic Processes (1)
EDP-305 (3) · Ethinyl Estradiol (2) · 2-chloro-3-(1-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)-6-oxo-5-phenyl-7H-thieno)(2,3-b)pyridin-4-olate potassium (1) · ALT-801 (1) · Atorvastatin (1) · Canrenoic Acid (1) · Contraceptives, Oral (1) · Digoxin (1) · Fluconazole (1) · Levonorgestrel (1) · Metformin (1) · Quinidine (1) · Rifampin (1) · Technetium Tc 99m Sulfur Colloid (1) · Warfarin (1)
Enanta Pharmaceuticals, Inc (4) · Rivus Pharmaceuticals, Inc. (2) · 89bio, Inc. (1) · Aligos Therapeutics (1) · Altimmune, Inc. (1) · Blade Therapeutics (1) · Cellaion SA (1) · Elif Oral (1) · Enyo Pharma (1) · Madrigal Pharmaceuticals, Inc. (1) · Navidea Biopharmaceuticals (1) · Poxel SA (1) · Sinew Pharma Inc. (1) · Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1) · University of California, San Francisco (1)
United States (12) · Australia (3) · France (2) · Belgium (1) · Bulgaria (1) · Spain (1) · Taiwan (1) · United Kingdom (1)
Amy Eastenson, MD (1) · Elif A Oral, M.D. (1) · Mark Matson, MD (1) · Michael Blue, MD (1) · Monika A Sarkar (1)